Pharmaceuticals

2025–2029 Connected Drug Delivery Devices Market Outlook: Regional Trends and Growth Forecast

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Connected Drug Delivery Devices Industry?#_x000D_

The market size for complement inhibitors has seen a dramatic rise in recent years. It is anticipated to increase from $16.41 billion in 2024 to $21.26 billion in 2025, marking a compound annual growth rate (CAGR) of 29.6%. The past growth can be linked to a rising prevalence of diseases mediated by complement, heightened awareness about rare illnesses, the introduction of biologics as potent treatments, an uptick in healthcare spending, increased attention on personalized healthcare, the presence of incentives for orphan drugs, government support for rare disease therapies, and partnerships among pharmaceutical firms and research establishments._x000D_

_x000D_

The market for complement inhibitors is predicted to experience significant expansion in the ensuing years, ballooning to “$60.28 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 29.8%. This anticipated growth during the projection period is linked to the growing prevalence of autoimmune and inflammatory diseases, expansion of biologics and biosimilar markets, increase in clinical trial activity, development of potent next-gen complement inhibitors, expansion of healthcare facilities in burgeoning markets, boosting adoption of precision therapies, an ageing population, and wider patient access to biologic therapeutics. Key trends to watch during the forecast period span from artificial intelligence-assisted drug discovery to advanced biomarker identification methods, machine learning for predicting patient reaction, long-action drug formulations, next-generation sequencing for complement system examination, high-speed screening platforms, organ-on-a-chip models for testing complement inhibitors, 3D bioprinting techniques for the production of complement inhibitors, and instant monitoring tools to gauge treatment success._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21155&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Connected Drug Delivery Devices Industry?#_x000D_

The rising significance of remote patient monitoring is anticipated to boost the progress of the connected drug delivery device market. This healthcare approach leverages technology to remotely monitor patients’ health and medical information. By allowing accurate tracking of medication use and compliance, offering timely interventions, and delivering personalized care management, connected drug delivery devices enhance remote patient monitoring. For example, as per a survey by Vivalink Inc., a US firm specializing in digital health solutions, there was a 305% surge in clinicians employing remote patient monitoring from 20% in 2021 to 81% currently. This happened in August 2023, and 84% of these users intend to broaden their RPM usage in 2024. Consequently, the rising significance of remote patient monitoring is fueling the expansion of the connected drug delivery device market._x000D_

_x000D_

The complement inhibitors market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Complement Component 3 (C3) Inhibitors, Complement Component 5 (C5) Inhibitors, Complement Factor D Inhibitors_x000D_

2) By Mechanism Of Action: Alternative Pathway Inhibitors, Classic Pathway Inhibitors, Lectin Pathway Inhibitors_x000D_

3) By Indication: Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Paroxysmal Nocturnal Hemoglobinuria (PNH)_x000D_

4) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)_x000D_

5) By Patient Demographics: Adult, Geriatric, Pediatric_x000D_

_x000D_

Subsegments:_x000D_

1) By Complement Component 3 (C3) Inhibitors: Small Molecule C3 Inhibitors, Monoclonal Antibody C3 Inhibitors, Peptide-Based C3 Inhibitors _x000D_

2) By Complement Component 5 (C5) Inhibitors: Monoclonal Antibody C5 Inhibitors, Small Molecule C5 Inhibitors, RNA-Based C5 Inhibitors _x000D_

3) By Complement Factor D Inhibitors: Small Molecule Factor D Inhibitors, Monoclonal Antibody Factor D Inhibitors_x000D_

_x000D_

#Which Trends Are Redefining The Future Landscape Of The Connected Drug Delivery Devices Industry?#_x000D_

Prominent operators in the complement inhibitors market, such as F. Hoffmann-La Roche AG, are shifting their attention toward the development of monoclonal antibodies. These specially engineered proteins have the ability to specifically target and regulate the complement system, especially in connection with a number of autoimmune and inflammatory illnesses. They are proven effective in treating infections, cancer and autoimmune diseases. In August 2024, F. Hoffmann-La Roche AG, a pharmaceutical firm originating in Switzerland, acquired approval from the European Commission to provide PiaSky (crovalimab) to adults and adolescents diagnosed with paroxysmal nocturnal haemoglobinuria (PNH). These patients are either new or have previously been treated with C5 inhibitors. The purpose of PiaSky (crovalimab), a monoclonal antibody, is to aim at the complement protein C5, to inhibit the breakdown of this substance and thus blocking the creation of the membrane attack complex (MAC). Consequently, this limits the terminal complement-mediated intravascular haemolysis. PiaSky’s primary job is to inhibit haemolysis. This allows PiaSky to enhance hemoglobin levels, minimize the demand for blood transfusions and relieve symptoms such as fatigue and anemia, which significantly boosts the quality of life among patients._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Connected Drug Delivery Devices Market?#_x000D_

Major companies operating in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/complement-inhibitors-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Connected Drug Delivery Devices Market Through 2029?#_x000D_

North America was the largest region in the complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complement inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21155&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_